Search

Your search keyword '"Foschi, F.G."' showing total 42 results

Search Constraints

Start Over You searched for: Author "Foschi, F.G." Remove constraint Author: "Foschi, F.G." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
42 results on '"Foschi, F.G."'

Search Results

1. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

2. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

3. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

4. 88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

7. Impaired tuftsin activity in cirrhosis: Relationship with splenic function and clinical outcome. (Liver Disease)

18. Anti-endothelial cell antibodies in Crohn's disease

21. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery

22. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

23. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?

24. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment

25. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

26. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

27. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

28. Identification of clinical phenotypes and related survival in patients with large hccs

29. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

30. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

31. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients

32. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

33. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

34. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

35. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients

36. Platelets and hepatocellular cancer: Bridging the bench to the clinics

37. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

38. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

39. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study

40. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older

41. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

42. Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice

Catalog

Books, media, physical & digital resources